ASH 2014 | ASH 2014: Phase II study of lenalidomide plus rituximab for mantle cell lymphoma (Part 2)

Name: ASH 2014: Phase II study of lenalidomide plus rituximab for mantle cell lymphoma (Part 2)
Uploaded: 2014-12-05T00:00:00Z
Duration: 2 min 48 s
Description: Dr Jia Ruan (Weill Cornell Medical College, New York, NY) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses the clinical relevance of a phase II study of the biologic doublet, lenalidomide plus rituximab, as initial treatment for mantle cell lymphoma.

Jia Ruan • 5 Dec 2014

ASH 2014

Mantle Cell Lymphoma Antibodies Lenalidomide Rituximab

Dr Jia Ruan (Weill Cornell Medical College, New York, NY) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses the clinical relevance of a phase II study of the biologic doublet, lenalidomide plus rituximab, as initial treatment for mantle cell lymphoma.